Purpose
A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-500, an oral FLT3 inhibitor, in adult patients with acute leukemia.
Full Title
A Phase 1, open-label, dose-escalation, and dose-expansion study of BMF-500, an oral covalent FLT3 inhibitor, in adults with acute leukemia
ClinicalTrials.Gov ID
NCT05918692
To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.